Statin therapy discontinuation before pregnancy presents clinical dilemma balancing theoretical fetal teratogenicity against maternal cardiovascular risk, particularly among women with familial hypercholesterolemia or established atherosclerotic cardiovascular disease. Current guidelines universally recommend cessation at pregnancy confirmation despite limited prospective comparative effectiveness data. 
In the study published in the Circulation, the South Korean investigators analyzed National Health Insurance Database records spanning 2009-2023, identifying 13,374 women with 12-24 weeks preconception statin exposure who conceived between 2010-2022. Participants stratified by statin continuation beyond last menstrual period (56.0%, n=7,493) versus discontinuation prior to LMP (44.0%, n=5,881). 
Primary maternal outcome comprised major adverse cardiovascular and cerebrovascular events including myocardial infarction, stroke, coronary revascularization, and cardiovascular death. Gestational endpoints captured preterm delivery, hypertensive disorders, gestational diabetes, nonlive birth, congenital malformations, and low birth weight. 
Maternal Cardiovascular Risk Neutrality Confirmed
Statin discontinuation demonstrated no association with increased maternal MACCE versus continuation (hazard ratio 1.00, 95% CI 0.72-1.37), establishing cardiovascular safety across overall cohort. High-risk subgroups confirmed consistency: familial hypercholesterolemia patients showed hazard ratio 0.92 (95% CI 0.46-1.85); atherosclerotic cardiovascular disease subgroup yielded hazard ratio 0.83 (95% CI 0.46-1.49). These findings alleviate concerns regarding acute withdrawal rebound among vulnerable women.
Fetal Outcomes Favor Discontinuation Strategy
Secondary analyses revealed lower nonlive birth risk (risk ratio 0.89, 95% CI 0.82-0.95) and reduced low birth weight incidence (risk ratio 0.88, 95% CI 0.78-0.99) among discontinuation group, though observational design precludes causal attribution. Gestational diabetes, hypertensive disorders, preterm delivery, and malformation rates demonstrated no significant between-group differences.
Mechanistic Insights Into Pregnancy Safety
Statin withdrawal avoids first-trimester cholesterol synthesis inhibition during organogenesis while preserving preconception atheroprotection. Short-term discontinuation appears insufficient to precipitate plaque destabilization given residual lipoprotein effects and pregnancy-associated lipid elevations mitigating acute risk.
Preconception Counseling Paradigm Shift
Cardiologists, maternal-fetal medicine specialists, and lipidologists gain population-level reassurance supporting guideline-concordant statin cessation without maternal penalty. Preconception optimization through aggressive lifestyle intervention, ezetimibe, or PCSK9 inhibition facilitates seamless transition for high-risk women. Postpartum reinitiation timing optimizes long-term cardiovascular protection while minimizing fetal exposure. Shared decision-making incorporates individualized absolute risk alongside reassuring comparative safety data.
Implementation Through Risk-Stratified Protocols
Health systems should institutionalize preconception statin counseling protocols integrating absolute event rates, subgroup consistency, and secondary fetal signal. Electronic health record alerts facilitate medication reconciliation while multidisciplinary clinics coordinate high-risk transitions, ensuring guideline adherence translates into optimal maternal-fetal outcomes across diverse cardiovascular risk spectra.